|
|
|
|
|
|
|
|
|
|
med news
Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor
Therapy for Cancer
WHITEHOUSE STATION, N.J. & LONDON--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and AstraZeneca (NYSE: AZN) today announced a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard-of-care therapies for the treatment of patients with certain types of ovarian cancer......
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.